Host response dynamics following lethal infection of rhesus macaques with zaire ebolavirus by Ebihara, H. (Hideki) et al.
S U P P L E M E N T A R T I C L E
Host Response Dynamics Following Lethal
Infection of Rhesus Macaques With Zaire
ebolavirus
Hideki Ebihara,1 Barry Rockx,1,a Andrea Marzi,1 Friederike Feldmann,2 Elaine Haddock,1 Douglas Brining,3
Rachel A. LaCasse,3 Don Gardner,3 and Heinz Feldmann1
1Laboratory of Virology, 2Office of Research Operation, and 3Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute
of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
To gain further insight into the interdependent pathogenic processes in Ebola hemorrhagic fever (EHF), we have
examined the dynamics of host responses in individual rhesus macaques infected with Zaire ebolavirus over the
entire disease course. Examination of coagulation parameters revealed that decreased coagulation inhibitor
activity triggered severe coagulopathy as indicated by prolonged coagulation times and decreased fibrinogen
levels. This has been proposed as one of the significant mechanisms underlying disseminated intravascular
coagulation in EHF patients. Furthermore, monitoring of expression levels for cytokines/chemokines suggested
a mixed anti-inflammatory response syndrome (MARS), which indicates that a catastrophic uncontrolled
immunological status contributes to the development of fatal hemorrhagic fever. These results highlight the
pathological analogies between EHF and severe sepsis and not only contribute to our understanding of the
pathogenic process, but will also help to establish novel postexposure treatment modalities.
Zaire ebolavirus (ZEBOV) infections result in case-fatality
rates of up to 90%, making this one of the most severe
viral hemorrhagic fevers (VHFs) worldwide [1, 2]. Gaining
further insight into the details of interdependent patho-
genic processes, including both the host immune and
pathophysiological responses, involved in triggering
this severe hemorrhagic syndrome is essential for the
development of effective countermeasures for Ebola
hemorrhagic fever (EHF) [2, 3].
Currently, the nonhuman primate (NHP) is the gold
standard animal model for studying pathogenesis and
developing countermeasures [4]. NHPs are both highly
susceptible to ZEBOV infection (nearly 100% lethality)
and show the hallmarks of human EHF [5–7]. To date,
both cynomolgus (Macaca fascicularis) and rhesus
(Macaca mulatta) macaques have been used for the
development of countermeasures against EHF, while
characterization of the pathogenic processes in NHPs
infected with ZEBOV has mainly been carried out in
cynomolgus macaques [6–8]. In contrast to cynomolgus
macaques, detailed studies on pathogenesis with rhesus
macaques, which are often used for postexposure
treatment studies [9–12], have not been carried out,
with a few exceptions from the early literature [13–16].
Several serial sacrifice studies have been conducted using
cynomolgus macaque models to elucidate the patho-
genic processes associated with ZEBOV infection. These
studies have provided us with significant insights into
the role of primary target cells in pathogenesis and
the mechanisms underlying coagulation abnormalities
[6–8]. On the other hand, continuous monitoring of
immunological and pathophysiological host responses
in individually infected animals is important to fully
understand EHF pathogenesis [7, 14–16]. This cannot
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be achieved with serial sacrifice pathology studies, because of
the variable host responses in outbred animals such as NHPs.
To date, only a limited number of studies have been carried out
for the comprehensive monitoring of host responses in rhesus
macaques infected with ZEBOV [15, 16]. We, therefore, studied
the host response dynamics through daily monitoring of blood
biochemistry and coagulation parameters, as well as cytokine/
chemokine profiles in individual animals over time. The new data
obtained here advance our understanding of the pathogenesis of
ZEBOV infection in macaques and will facilitate development
of novel postexposure treatment strategies to combat EHF.
MATERIALS AND METHODS
Cells and Viruses
Vero E6 (African green monkey kidney) cells were grown and
maintained at 37C in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, L-glutamine,
penicillin, and streptomycin. The Mayinga strain of ZEBOV
was grown in Vero E6 cells. Virus infectivity titers, expressed
as focus-forming units (FFU), were obtained by counting the
number of infected cell foci detected using an indirect immu-
nofluorescent antibody assay with a rabbit polyclonal anti-
ebolavirus (EBOV) VP40 as previously described [17].
Nonhuman Primate Experiments
Three healthy, filovirus-seronegative, male rhesus macaques
designated as subjects 14, 15, and 16, weighing 10.0, 9.4, and
12.0 kg, respectively, were inoculated in the caudal thigh with
1 mL of virus stock containing 1000 FFU of ZEBOV. The ani-
mals were monitored daily through clinical scoring (non-
anesthetized) and clinical examination (anesthetized). Clinical
examinations included body temperature, blood pressure, heart
rate, respiration rate, pulse oximetry, venous bleeding, and
collection of swabs from nasal, oral, and rectal mucosa. The
preclinical examinations were done 2 days before and simulta-
neously with infection (day 0). All animals were euthanized
when clinical signs indicated terminal disease according to an
approved endpoint-scoring sheet. Upon necropsy, various tis-
sues were collected for virological assays. Infectivity titers from
all blood, swab, and tissue samples were determined by median
tissue culture infective dose (TCID50) assay on Vero E6 cells.
Hematology, Blood Biochemistry, and Coagulation Parameter
Assays
Hematological and serum biochemical analysis was carried out
following standard protocols [7]. Hematological values and pa-
rameters were determined from EDTA blood with the HemaVet
950FS1 laser-based hematology analyzer (Drew Scientific).
Blood chemistry values were analyzed from heparinized whole
blood using the blood chemistry analyzer iSTAT1 (Abbott Point
of Care) with the EC81 and Crea cartridges. Blood samples for
the coagulation parameter assays were collected into 1.8-mL
citrate vacutainers. Plasma was separated by centrifugation and
analyzed for activated partial thromboplastin time (aPTT),
prothrombin time (PT), thrombin time (TT), fibrinogen con-
centration, and protein S and protein C activity with the STart4
instrument using the PTT Automate, STA Neoplastine CI plus,
STA Thrombin, Fibri-Prest automate, and STA Staclot protein
S and protein C kits, respectively (all from Diagnostica Stago).
Plasma Cytokine and Chemokine Analysis
Plasma samples for cytokine assay were inactivated by
c-irradiation (5 mrad) prior to removal from Biosafety Level 4
(BSL4) for further analysis. Concentrations of granulocyte colony-
stimulating factor, granulocyte-macrophage colony-stimulating
factor, interferon (IFN)–c, interleukin (IL)–1b, IL-1 receptor
antagonist, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40),
IL-13, IL-15, IL-17, MCP-1 and macrophage inflammatory
protein (MIP)–1a, MIP-1b, soluble CD40-ligand (sCD40L),
transforming growth factor-a, tumor necrosis factor (TNF)–a,
vascular endothelial growth factor (VEGF), and IL-18 were
measured on a Bio-Plex 200 instrument (Bio-Rad) using the
Non-Human Primate Cytokine MILLIPLEX map kit (Milli-
pore) according to the manufacturer’s instructions.
Biosafety and Animal Ethics
All in vitro and in vivo work with infectious ZEBOV was
performed in the BSL4 laboratories of the Integrated Research
Facility of the Rocky Mountain Laboratories, Division of
Intramural Research, National Institute of Allergy and Infectious
Diseases, National Institutes of Health. All animal work was
approved by the local Institutional Animal Care and Use
Committee (IACUC) and performed following the guidelines of
the Association for Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC) by certified staff in an
AALAC-approved facility.
RESULTS
Clinical Signs, Disease Progression, and Viremia in Infected
Rhesus Macaques
The clinical, hematological, and virological findings are sum-
marized in Figure 1A. Signs of illness were visible starting from
days 2–3 after infection. All 3 animals became febrile (.40C)
between days 2 and 4 and remained febrile until euthanized. The
first hemorrhagic manifestations observed were bleeding signs,
such as blood on nasal or rectal swabs, which were observed
on day 3 for subjects 14 and 15, and on day 5 for subject 16
(Figure 1A). Following the appearance of early bleeding signs, all
animals developed a macular cutaneous rash/petechia on several
body parts (eg, arms, chest, groin, thorax, and face) starting
between days 4 and 7 . In consultation with the facility veteri-
narian, animals were euthanized according to a predetermined
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clinical humane endpoint-scoring sheet when clinical disease
progression was considered irreversible (subject 14 on day 6.5,
15 on day 6, and 16 on day 7) (Figure 1A). Necropsy findings
and gross pathological changes were consistent with the ob-
servations reported previously [7, 13].
Total white blood cell (WBC) counts peaked between days
3 and 4 and indicated leukocytosis (Figure 1B). Differential
WBC counts confirmed leukocytosis mainly due to neutrophilia
(Figure 1C). Concomitantly, lymphocytopenia was observed
as differential lymphocyte counts dropped from day 2 to day 5
Figure 1. Disease progression in rhesus macaques following Zaire ebolavirus (ZEBOV) infection. Three rhesus macaques (subjects 14, 15, and 16) were
infected via intramuscular injection with 1000 focus-forming units of ZEBOV (Mayinga strain). Clinical examination and sample collections were
performed daily until animals were euthanized. (A) Disease progression and clinical presentations. Dagger: euthanasia, when clinical signs indicated
terminal disease according to an endpoint-scoring sheet. (B ) Total white blood cell (WBC) and lymphocyte (LY) counts. (C ) Differential neutrophil (NE) and
LY counts. (D ) Platelet (PLT) counts. (E ) Viremia. Viral infectivity titration was performed on Vero E6 cells by use of a median tissue culture infective dose
(TCID50) assay. Infectivity titers are presented as log10 TCID50/mL.
Host Response to Ebola Infection in Macaques d JID 2011:204 (Suppl 3) d S993
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/204/suppl_3/S991/2192725 by Erasm
us U
niversiteit R
otterdam
 user on 03 June 2019
(Figure 1C ). Thrombocytopenia developed between days 3
and 4 with cell counts dropping below 150 000 or even 100 000
(Figure 1D). These findings were consistent with the observations
in cynomolgus and rhesus macaques reported previously [7, 15].
Plasma viremia was first detected on day 3 in subject 15. This
animal was also the first to succumb to the infection. In subjects
14 and 16, viremia was delayed, starting on day 5 (Figure 1E).
Viremia levels constantly increased and peaked at the time of
euthanasia, ranging from 106 to 108 TCID50/mL. At necropsy,
various tissues (40 tissues per animal) were collected and in-
fectious virus was detected in all tissues with titers ranging from
approximately 104 to 108 TCID50/g (data not shown).
Coagulation Abnormalities in Infected Rhesus Macaques
We further examined coagulation parameters, including PT,
aPTT, TT, fibrinogen level, and protein C and S coagulation
inhibitor activity in plasma of infected animals. Changes over
baseline were observed in all parameters tested starting between
days 3 and 4 (Figure 2, A–C). The clotting time parameters PT,
aPTT, and TT were prolonged in all animals starting at day 3 for
PT and aPTT and day 5 for TT (Figure 2). Fibrinogen levels were
increased and peaked on days 4–5, then strikingly declined
to below the detection limit in the terminal stage of illness
(Figure 2D). A rapid decline in protein C activity was observed
in all animals on day 3, whereas decline in protein S activity
was moderate and not distinct (Figure 2, E and F). Subject 15
showed low levels of protein C and S activity until the terminal
stage of infection, whereas the levels in subjects 14 and 16 ap-
peared to slightly rebound between days 4 and 6 and then
rapidly decline during the terminal stage of illness (Figure 2,
E and F). These parameters indicate that ZEBOV-infected
animals displayed severe dysfunctions in coagulation
Figure 2. Development of coagulation abnormalities in rhesus macaques during Zaire ebolavirus (Mayinga strain) infection. (A) Prothrombin time (PT).
(B ) Activated partial thromboplastin time (aPTT). (C ) Thrombin time (TT). (D ) Fibrinogen concentration in plasma. (E ) Plasma protein C coagulation inhibitor
activity. The y-axis describes values as percentage of normal human coagulation inhibitor activity. (F ) Plasma protein S coagulation inhibitor activity. The
y-axis describes values as percentage of normal human coagulation inhibitor activity.
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resembling disseminated intravascular coagulation (DIC),
although confirmation of DIC ideally includes detection of
fibrin split products and D-dimers.
Cytokine and Chemokine Profiles in Infected Rhesus Macaques
To examine the correlation between clinical disease progression,
coagulation, and host immune responses, we monitored the
expression of cytokines, chemokines, and other soluble media-
tors in the plasma of infected animals. Twelve of the 23 soluble
mediators examined showed significant changes from baseline
values (day –2 and day 0 at challenge). First, plasma levels
of representative proinflammatory cytokines and chemokines
(IL-1b, IL-6, MIP-1a, and TNF-a), which are upregulated
during EHF in humans [18–20], were examined. IL-1b, IL-6,
and MIP-1a were elevated from day 4 onward in all infected
animals (Figure 3, A–D), whereas TNF-a was only detected
during the terminal stage of infection (days 5 and 6) and only
in 2 of the 3 animals (Figure 3C).
Among the proinflammatory cytokines associated with T cell
activation, IFN-c and IL-15 were found to be elevated between
days 2 and 4 in all animals (Figure 4, A and C). Subject 16 showed
massive expression of IFN-c in the terminal disease stage. In
subjects 14 and 16, the level of IL-15 peaked between days 4 and 5,
then declined before the animal entered the terminal disease stage
(Figure 4C). Interestingly, decreased levels of IL-12/23 p40 were
observed in all infected animals from day 1 and those levels
continuously decreased until animals succumbed to the infection
(Figure 4B). All animals showed elevated IL-18 levels beginning
between days 3 and 4, but the levels varied over time and among
animals (Figure 4D). In subject 14, IL-18 levels peaked on day 6
and then rapidly declined immediately before the animal suc-
cumbed to infection. Subject 15 showed the smallest increase in
levels of IL-18. Interestingly, the elevation of IL-18 levels in subject
16 was biphasic (Figure 4D).
Anti-inflammatory responses were also upregulated in all
infected animals. While IL-13 and IL-1 receptor antagonist
(IL-1ra) levels were increased from day 2 in all animals
(Figure 5, B and C), the expression kinetics of IL-10 was totally
different among the 3 animals (Figure 5A). Subject 15, which
showed the shortest survival time, had increased IL-10 expres-
sion beginning at day 1, whereas subject 14 showed decreased
levels of IL-10 at early stages of infection and then rebounded
at the terminal stage of infection. Subject 16 had elevated IL-10
expression only in the terminal disease stage (Figure 5A).
Finally, we also monitored soluble CD40-ligand as a marker
for platelet activation [21]. Overall, sCD40L levels were in-
creased in the early stage of infection (Figure 5D), and then
decreased in the late to terminal stages of disease, which were
also associated with thrombocytopenia in 2 of 3 animals, both
showing a prolonged period with hemorrhagic signs (Figure 1A,
subjects 14 and 15; Figure 1D). Subject 14 showed high levels
of sCD40L expression prior to infection. Levels then rapidly
Figure 3. Kinetics of plasma proinflammatory cytokine and chemokine levels in rhesus macaques following Zaire ebolavirus (Mayinga strain) infection.
(A) IL-1b, (B ) IL-6, (C ) TNF-a, (D ) MIP-1a. IL, interleukin; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor.
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declined until day 3 when they rebounded and declined again
toward the terminal stage of disease. In subject 15, sCD40L
levels peaked on day 2 and then rapidly declined toward the
terminal stage of disease. Subject 16 only showed a transient
increase in sCD40L levels and maintained a low level of
sCD40L throughout the infection (Figure 5D).
DISCUSSION
In the present study, we investigated the dynamics of
pathogenesis-related host responses occurring during ZEBOV
infection through daily monitoring of multiple parameters in
individual rhesus macaques throughout the entire disease
course. It is noteworthy that the time to death (average 6.5 days)
of rhesus macaques infected with the ZEBOV Mayinga strain
in the present study was shorter than that of recent rhesus
macaque studies with the ZEBOV-95 Kikwit strain (average
8.4 days) [9–12]. A shorter time to death in rhesus macaques
infected with another ZEBOV-76 strain was also observed in
previous studies [13–16]. These data suggest that ZEBOV-76
strains might be more virulent than ZEBOV-95 in rhesus
macaques.
Among the pathological processes examined in this study, the
coagulation disorders are believed to be key pathogenic events
responsible for inducing lethal disease in humans and NHPs
infected with ZEBOV [3, 6, 8, 22]. We show here that
thrombocytopenia was temporally associated with the appear-
ances of abnormalities in coagulation parameters, including
prolonged PT, aPTT, and TT (Figure 1D and Figure 2, A–C).
Notably, decline in protein C coagulation inhibitor activity due
to its consumption occurred 1 to 2 days prior to prolongation in
coagulation times (Figure 2, A–E). This suggests that enhance-
ment of the procoagulant state, an event that has been proposed
as an important mechanism for DIC development, might
trigger severe coagulation impairment in the infected animals
[3, 6, 8, 22]. Therefore, ZEBOV infection in NHPs (8; this
study) behaves similarly to severe sepsis, where protein C is also
consumed and/or production of protein C is decreased during
systemic coagulopathy [23–25]. In addition to being a regulator
of coagulation, protein C has also been reported to have anti-
inflammatory, antiapoptotic, and cytoprotective activities [26, 27].
Particularly for sepsis, the anti-inflammatory function of
protein C is thought to play an important role in controlling
severe inflammatory responses that lead to hypercoagulation
[24, 28]. Here and in other studies [7, 18, 20] it has been
reported that aberrant inflammatory/anti-inflammatory re-
sponses are a hallmark of ebolavirus infection, suggesting that
reduced protein C activity may contribute to severe disease
progression through defective control of coagulation and severe
inflammatory responses. Moreover, protein C and fibrinogen
(see below) are synthesized in the liver [24], where the hepatic
synthesis of both protein C and fibrinogen have been reported
Figure 4. Kinetics of plasma proinflammatory cytokine and chemokine levels activating T cells in rhesus macaques following Zaire ebolavirus (Mayinga
strain) infection. (A) IFN-c, (B ) IL-12/23 p40, (C ) IL-15, (D ) IL-18. IFN, interferon; IL, interleukin.
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to be reduced in cases of septic liver dysfunction [24]. The liver
is a main target organ for filovirus infection, with pathological
changes that include severe hepatocellular degeneration and
necrosis with inflammation, most likely resulting in decreased
production of protein C and fibrinogen (see below) [7, 24, 29].
Supporting these concepts, postexposure treatment of ZEBOV-
infected rhesus macaques with recombinant human activated
protein C was found to protect 18% of animals and resulted in
a significantly prolonged survival time with decreased plasma
fibrin degradation products (D-dimer levels) in animals that
succumbed to infection [30]. Similarly, activated protein C
reduced the relative risk for lethal outcome among patients
with sepsis and DIC by 38% [25]. Altogether, impaired protein
C and S activities and the effect on coagulation and in-
flammatory responses are common pathogenic processes of
severe sepsis/septic shock and filoviral hemorrhagic fever.
Another striking finding in ZEBOV-infected rhesus macaques
was the rapid reduction of plasma fibrinogen levels in the terminal
stage of disease following an initial abnormal increase in fibrinogen
levels (Figure 2D). Plasma fibrinogen concentrations decline
due to the subsequent generation of large amounts of fibrin by
the conversion of fibrinogen. This observation clearly suggests the
induction of uncontrolled coagulation in ZEBOV-infected ani-
mals. Widespread intravascular fibrin deposition is a hallmark of
DIC during severe sepsis [24, 31] and, similarly, both fibrin de-
position in tissues and rapid increases in D-dimer plasma levels
were observed in ZEBOV-infected cynomolgus macaques [8].
Thus, consumption of plasma fibrinogen indirectly reflects pro-
gression to DIC. Hypofibrinogenemia, however, can only be de-
tected in a limited number of severe DIC cases, because levels of
fibrinogen, an acute-phase reactant, are generally elevated during
systemic inflammatory response syndrome (SIRS), such as in
sepsis and VHFs [23, 25]. Therefore, in certain circumstances,
apparently normal fibrinogen plasma levels may actually conceal
fibrinogen consumption. In fact, fibrinogen concentrations were
increased before the ZEBOV-infected animals entered the ter-
minal stage of illness (Figure 2D), which might be explained by
the strong systemic inflammatory response during infection
(Figures 3 and 4). Nevertheless, infected animals showed a dra-
matic drop in fibrinogen during the terminal disease stage,
suggesting uncontrolled coagulopathy as a result of ZEBOV in-
fection.
Aberrant cytokine/chemokine responses are thought to be an-
other significant factor for disease progression in EHF cases and
experimentally infected nonhuman primates [5, 18–20, 32, 33].
The most consistent observation is uncontrolled systemic
inflammatory responses (hypersecretion/cytokine storm) re-
sembling SIRS, which may represent a critical factor in the
induction of vascular leakage, coagulation abnormalities (DIC),
and multiorgan failure [1, 3, 5, 7, 18–20, 22, 32–34]. In
our present study, upregulated proinflammatory cytokines/
chemokines included IL-1b, IL-6, MIP-1a, IL-15, and IL-18
Figure 5. Kinetics of plasma anti-inflammatory mediators, and soluble CD40 ligand (sCD40L) levels in rhesus macaques following Zaire ebolavirus
(Mayinga strain) infection. (A) IL-10, (B ) IL-13, (C ) IL-1 receptor antagonist (IL-1ra), (D ) sCD40L. IL, interleukin.
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(Figures 3 and 4), which have been previously reported to be
upregulated in EHF patients [18, 19, 32, 33] and experimentally
infected cynomolgus macaques [7]. Interestingly, TNF-a, which
has been recognized as a critical cytokine for VHF pathogenesis,
was only detected in 2 of 3 animals at the terminal disease
stage (Figure 3C). The role of TNF-a in EHF remains contro-
versial [18–20, 32–34]. Data from outbreaks in Gabon (1996)
and the Democratic Republic of the Congo (1995) associated
moderate to high plasma levels of TNF-a with fatal outcomes
[19, 20]. In contrast, investigations of later outbreaks in Gabon
and the Republic of Congo [18] as well as the Sudan ebolavirus
outbreak in Uganda, did not find the same association [32, 33].
In addition, early moderate levels of TNF-a have been
described as key immune responses in survivors of Zaire EHF
and asymptomatic EBOV infections [19, 35], suggesting that
a TNF-a response in the late stages of infection might be
deleterious and contribute to lethal disease progression. TNF-a
is also produced by EBOV and Marburg virus (MARV)–infected
monocytes and was shown to increase endothelial cell perme-
ability in a tissue culture system [36, 37]. This may suggest
that TNF-a triggers abnormal vascular leakage in EHF patients
and infected macaques [1, 5, 6]. In contrast to other proin-
flammatory mediators, plasma levels of the p40 subunit of
IL-12 and IL-23 were decreased in all infected animals
(Figure 4B). Both of these cytokines are released from
dendritic cells and regulate innate and adaptive immunity [38].
Therefore, depression of both cytokines in the plasma
of ZEBOV-infected macaques may reflect impaired dendritic
cell function, a premise that is supported by in vitro studies
showing that ZEBOV infection or expression of ZEBOV VP35 in
dendritic cells impaired their maturation and suppressed IL-12
expression [39–42].
Synchronous proinflammatory and anti-inflammatory re-
sponses have been previously reported as an abnormality in the
immunological status of EHF patients [18–20]. Our study supports
the finding that the induction of a SIRS-like syndrome during
EBOV infection might induce a hypoinflammatory status referred
to as compensatory anti-inflammatory response syndrome [43],
which itself is known to trigger an abnormal immunological status
known as mixed anti-inflammatory response syndrome (MARS)
[43, 44]. MARS has also been described in severe sepsis cases and
may be a marker for early mortality [42–44]. In the present study,
IL-13 and IL-1ra levels were highly elevated in infected macaques
(Figure 5, B and C). This suggests that MARS may contribute
to pathogenesis in EHF. Notably, increased levels of anti-
inflammatory cytokines including IL-10 and IL-13 were as-
sociated with fatal EBOV cases, and were related to severity
and fatality in sepsis patients [19, 20, 32, 45], although levels of
IL-10 were variable among the 3 animals in this study. These
findings emphasize the potential for preventing the progression
to MARS by controlling the development of SIRS as a treatment
option for EHF.
Similar to anti-inflammatory mediators, higher plasma levels
of sCD40L, a known marker of platelet activation [21], were
found in 2 animals (subjects 14 and 15), although levels of
sCD40L were variable and inconclusive among the 3 animals
(Figure 5D). This implies that platelet activation might play
a role in the pathogenesis of EHF. Increased sCD40L levels have
also been observed in patients with acute coronary syndrome,
SIRS, and septic shock [21, 46]. In acute coronary syndrome,
circulating sCD40L levels were strongly associated with higher
neutrophil counts (neutrophilia) [46]. This was also observed
in ZEBOV-infected macaques (Figure 1C) [7, 15], further sug-
gesting that activation of platelets and/or sCD40L release might
lead to neutrophil activation and inflammation in infected
animals [47].
One of the guiding concepts in filoviral hemorrhagic fever
pathogenesis focuses on the pathophysiological and immuno-
logical similarities between EHF and severe sepsis [8, 22, 28, 48].
Our findings here further support these concepts and strongly
emphasize the pathophysiological analogies between filoviral
hemorrhagic fever, particularly EHF, and severe sepsis/septic
shock syndrome. Therefore, we propose that successful treat-
ment strategies for sepsis cases be evaluated in EHF animal
models and, if effective, be considered for treatment of EBOV
and MARV infections.
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